Acute myeloblastic leukemia secondary to myelodysplasia (MDS-AML): A comparison of remission induction with three drugs versus standard two-drugs induction

Roberto Latagliata, M. Breccia, A. Pulsoni, M. A. Aloe Spiriti, G. M. D'Elia, A. Spadea, E. Montefusco, G. Luzi, P. Betrò, M. C. Petti

Research output: Contribution to journalArticle

Abstract

To evaluate the addition of a third drug to standard induction chemotherapy in patients with MDS-AML, 23 patients (males/females 13/10, median age 54.3 years, range 24-74 years, median MDS duration 9.8 months, range 2-39 months) who received a standard 2-drugs induction were compared with 23 patients (males/females 11/12, median age 45.6 months, range 21-60 years, median MDS duration 8.3 months, range 2-29 months) who received an intensified 3-drugs induction with etoposide. CR rate, median CR duration and median OS were similar in both groups (48% vs 56%, 4.8 vs 5.9 months, 6.5 vs 7.0 months respectively). Among responding patients, all but one, who underwent allogeneic bone marrow transplantation, relapsed. In conclusion, addition of a third drug (etoposide) does not seem to significantly improve the poor prognosis of MDS-AML patients.

Original languageEnglish
Pages (from-to)539-541
Number of pages3
JournalLeukemia and Lymphoma
Volume36
Issue number5-6
Publication statusPublished - 2000

    Fingerprint

Keywords

  • Acute myeloblastic leukemia
  • Cytosine arabinoside
  • Etoposide
  • MDS-AML
  • Myelodysplastic syndromes
  • Remission induction

ASJC Scopus subject areas

  • Cancer Research
  • Hematology
  • Oncology

Cite this

Latagliata, R., Breccia, M., Pulsoni, A., Aloe Spiriti, M. A., D'Elia, G. M., Spadea, A., Montefusco, E., Luzi, G., Betrò, P., & Petti, M. C. (2000). Acute myeloblastic leukemia secondary to myelodysplasia (MDS-AML): A comparison of remission induction with three drugs versus standard two-drugs induction. Leukemia and Lymphoma, 36(5-6), 539-541.